Small molecules which reverse Cytarabine treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00012093
TitleSmall molecules which reverse Cytarabine treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Cytarabine treatment in the diffuse large B cell lymphoma SKI-DLCL cells cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1e55de467bea600fb960a
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis Curatornbongio
CREEDS IDdrug:2599
Cell Typediffuse large B cell lymphoma SKI-DLCL cells
Drug NameCytarabine
DrugBank IDDB00987
Organismhuman
PubChem CID6253
SMILES IDC1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM132917, GSM132918, GSM132920
Perturbed SamplesGSM132949, GSM132950, GSM132953
Tools used in the analysis
Dataset Accession
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
Datasets used in the analysis
Keyword
Tool Name
GSE5681
Gene Expression Omnibus
Aplidin and cytarabine effect on diffuse large B cell lymphoma cell line
14
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.